Entegris, Inc. — 2012 Form 10-K
Business context and reporting period. Entegris develops and supplies products and materials that purify, protect, monitor and transport critical materials used mainly in semiconductor manufacturing. It reports three segments: Contamination Control Solutions (CCS), Microenvironments (ME) and Specialty Materials (SMD). This filing covers the fiscal year ended December 31, 2012; quarterly figures below refer to the fourth quarter ended December 31, 2012.
Financial performance and liquidity
- Full-year revenue and earnings: Net sales were $715.9 million, down 4% from $749.3 million in 2011. Operating income was $99.4 million (13.9% margin), versus $126.9 million (16.9%). Net income attributable to Entegris was $68.8 million, or $0.50 diluted EPS, compared with $123.8 million, or $0.91.
- Margins and costs: Gross profit was $307.4 million and gross margin was 42.9%, down from $325.9 million and 43.5%. SG&A increased 5% to $147.4 million; R&D increased 6% to $50.9 million. The 2012 SG&A included a $3.9 million CEO succession and transition charge.
- Fourth quarter: Net sales were $167.8 million, gross profit $66.5 million and gross margin 39.6%; operating income was $13.9 million and net income $11.3 million, or $0.08 diluted EPS. Q4 2011 sales were $163.9 million, while net income was $40.2 million, including a $21.0 million tax benefit from release of a deferred-tax valuation allowance.
- Cash flow and investment: Operating cash flow was $115.2 million, down from $157.3 million in 2011. Capital expenditures were $49.9 million, versus $30.3 million. Cash and cash equivalents were $330.4 million, with an additional $20.0 million in short-term investments at year-end.
- Liquidity and debt: Working capital was $486.1 million and the current ratio 6.21. Entegris reported no outstanding short- or long-term borrowings at year-end; it had a $30 million revolving facility and access to approximately $14 million equivalent of Japanese-yen credit lines, both undrawn. Management said available resources should cover working capital and investment needs for at least 12 months.
- Other measures: Adjusted EBITDA, a non-GAAP measure, was $141.0 million (19.7% of sales), down from $163.2 million (21.8%). Non-GAAP EPS was $0.55, compared with $0.79. These measures supplement, and are not substitutes for, GAAP results.
Material changes versus 2011
- Lower semiconductor capital spending and sluggish production weighed on sales, particularly in the second half. Capital-driven product sales fell 14%; unit-driven product sales rose 1%. Currency translation reduced reported sales by $8.5 million.
- CCS sales declined 5% to $461.8 million and segment profit fell 17% to $116.4 million. ME sales were broadly flat at $182.4 million, while segment profit rose 24% to $37.2 million, supported by higher royalty revenue and improved factory utilization. SMD sales fell 14% to $71.7 million and segment profit fell 33% to $12.2 million.
- The effective tax rate rose to 31.0% from 3.3%. The prior-year rate benefited from a $41.0 million tax benefit tied primarily to reduced valuation allowances on deferred tax assets.
- The CEO transition occurred in November 2012, when Bertrand Loy became CEO; the associated transition charge was $3.9 million. Entegris acquired the remaining 50% of its Taiwan EPT joint venture for $3.4 million in April 2012; its results were not material.
Outlook, commentary and risks
- Management provided no specific 2013 revenue or earnings guidance in the supplied filing text. It planned 2013 capital expenditures of approximately $60–70 million, including about $40 million to complete its 450mm technology center and advanced membrane and coatings facility.
- Management intended to continue investment in core membrane and coatings technologies and 450mm wafer handling. The 450mm market’s timing and adoption remain uncertain, and returns on related investments are not assured.
- A key execution risk is transferring membrane manufacturing from Millipore’s Bedford facility, where the lease and equipment-use rights expire March 31, 2014, to Entegris’s new facility. The transition requires capital, time and capacity management; disruption could affect production and customer deliveries.
- Other material risks include semiconductor cyclicality, modest order backlog and nonbinding customer forecasts, customer concentration (top ten represented 36% of 2012 sales), pricing and competition, dependence on limited-source materials, manufacturing interruptions, foreign-exchange exposure and international operating risks. No single customer accounted for 10% or more of annual sales.
- Cash of $113.0 million was held by foreign subsidiaries and considered indefinitely reinvested. The filing states that repatriation could incur U.S. tax. A $50 million 2013 share-repurchase authorization was approved; the initial plan covered up to $30 million.
- The company reported no legal proceedings believed to have a material impact. KPMG gave an unqualified opinion on the financial statements and internal controls; management also concluded controls were effective at year-end.
Important facts for investors to verify
- Whether semiconductor demand, especially capital spending, recovered after the 2012 second-half decline and how this affected segment sales and margins.
- Progress, remaining cost and schedule for the 450mm and membrane/coatings facilities, and readiness to complete the membrane manufacturing transition before March 2014.
- Cash-flow conversion and planned capital spending relative to the $60–70 million 2013 estimate and the $85 million credit-agreement capex limit.
- The sustainability of earnings after the unusually low 2011 tax rate and the status of deferred-tax assets, valuation allowances and unrecognized tax benefits.
- Execution and funding of the 2013 buyback, including actual repurchases and any impact on liquidity or share count.